Guideline

Impulse Dynamics Completes $136M Financing Round

Retrieved on: 
Wednesday, February 14, 2024

The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare.

Key Points: 
  • The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare.
  • This substantial investment reflects investor confidence in, and commitment to, the company’s vision and expansion.
  • “This round of funding will accelerate our business, both commercially and with our pipeline of advanced technology innovation,” said Jason Spees, CEO of Impulse Dynamics.
  • “We are thrilled by the ongoing support from top-tier investment groups for Impulse Dynamics,” said Shlomi Nachman, Chairman of the Board.

First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

Retrieved on: 
Tuesday, February 13, 2024

Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media

Key Points: 
  • Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media
    Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).
  • “GenePHIT will evaluate the safety and efficacy of AB-1002 in the largest number of patients to date and improve our understanding of gene therapy overall for the treatment of congestive heart failure.
  • “The enrollment of this first patient in the Phase II trial represents the culmination of many years of dedicated research and development in all aspects of cardiac gene therapy for congestive heart failure.
  • AB-1002 is manufactured by Viralgen Vector Core, S.L., a wholly owned and independently operated subsidiary of AskBio.

The Future of Single Chamber ICDs: BIOTRONIK Takes Unprecedented Market Stance with Proprietary DX Technology

Retrieved on: 
Monday, February 12, 2024

"We are very proud that our DX technology provides the only lead available on the market offering both ventricular pacing/defibrillation and atrial monitoring," said Ryan Walters, BIOTRONIK US President.

Key Points: 
  • "We are very proud that our DX technology provides the only lead available on the market offering both ventricular pacing/defibrillation and atrial monitoring," said Ryan Walters, BIOTRONIK US President.
  • "Due to DX´s ability to provide additional patient and clinical benefits, it became clear to us that we should be using DX technology with every BIOTRONIK single-chamber ICD."
  • Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial.
  • REACT DX registry: Real world REACTion to atrial high rate episodes detected in implantable cardioverter-defibrillator recipients with a DX lead.

Arab Pharmacovigilance Guideline Practical Requirements Training Course (ONLINE EVENT: June 13-14, 2024)

Retrieved on: 
Friday, February 9, 2024

DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Practical Requirements of the Arab Pharmacovigilance Guidelines Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Practical Requirements of the Arab Pharmacovigilance Guidelines Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • On 1 July 2015, the Common Arab Guidelines on good vigilance practices became effective.
  • The Guidelines represented fundamental changes to pharmacovigilance practice and followed many aspects of the EU guidelines of June 2012.
  • This intensive two-day course will look at the various topics and their practical application from the perspective of compliance with the requirements of the Regulatory Authorities.

GS1 US Releases Guidelines To Help Accelerate 2D Barcode Adoption in Healthcare, Apparel and General Merchandise Industries

Retrieved on: 
Wednesday, February 7, 2024

EWING, N.J., Feb. 7, 2024 /PRNewswire/ -- GS1 US has unveiled two new guidelines to help industry transition to more-advanced two-dimensional (2D) barcodes on product packaging in the U.S. healthcare, apparel and general merchandise sectors.

Key Points: 
  • EWING, N.J., Feb. 7, 2024 /PRNewswire/ -- GS1 US has unveiled two new guidelines to help industry transition to more-advanced two-dimensional (2D) barcodes on product packaging in the U.S. healthcare, apparel and general merchandise sectors.
  • This industry guidance for implementing 2D barcodes, such as QR codes and GS1 DataMatrix, will enhance supply chain visibility, efficiency and patient and consumer safety.
  • The guideline "Unlocking the Benefits of 2D Barcodes in Apparel and General Merchandise: Getting Brands and Retailers Ready for Sunrise 2027" was produced by a GS1 US Workgroup comprising retailers, brands and solution providers in the apparel and general merchandise industries.
  • This guideline provides stakeholders with practical advice for implementing 2D barcodes by 2027, a timeline set by the retail industry in collaboration with GS1 US to scan 2D barcodes at point-of-sale (POS).

Microplastics found in Nile River’s tilapia fish: new study

Retrieved on: 
Tuesday, February 6, 2024

The Nile’s two main tributaries, the Blue Nile and the White Nile, come together in Sudan’s capital city, Khartoum.

Key Points: 
  • The Nile’s two main tributaries, the Blue Nile and the White Nile, come together in Sudan’s capital city, Khartoum.
  • The Nile is not immune to the same pollutants that affect rivers all over the world.
  • To address this gap, I conducted a study to assess the presence of microplastics in the River Nile in Khartoum.
  • My students and I tested for the presence of microplastics in Nile tilapia.
  • This shows that the River Nile is contaminated with microplastics that can be consumed or absorbed in various ways by the tilapia and other aquatic organisms.

Our sample

  • We visited the Al-Mawrada fish market in the Omdurman area, which is also alongside the Nile.
  • The individual tracts were treated so they would digest any organic matter they contained without interfering with the analysis of microplastics.
  • Read more:
    Fish in a major South African river are full of microplastics

Shape, size and colour

  • The most common were very small (less than 1mm), fibrous – they appear slender and elongated – and coloured (dyed).
  • These characteristics make sense because of how fish and other aquatic organisms feed.
  • Read more:
    Lagos beaches have a microplastic pollution problem

    Nile tilapia are also more likely to consume particles that are within a similar size range as their natural prey, as well as the same shape and colour.

  • Their small size also makes it easier for them to move into organs like the liver.

Pollution sources

  • For starters, 65% of plastic waste in Khartoum is disposed of in open dumps.
  • That means untreated effluent from domestic, industrial and agricultural activities is another probable source of microplastic pollution.
  • However, waste disposal and collection practices are sorely lacking, so plastic litter from these leisure activities leaks into the river.

No easy fix

  • Tackling microplastic pollution is not easy.
  • It will require technological advances, as well as the collective efforts of consumers, producers, governments and the scientific community.
  • Governments must enforce waste management regulations and improve waste management practices, as well as helping to improve public awareness.


The project was funded by the Royal Society – UK.

2 Day Arab Pharmacovigilance Guideline Practical Requirements Training Course (ONLINE EVENT: June 13-14, 2024) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 6, 2024

The "Practical Requirements of the Arab Pharmacovigilance Guidelines Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Practical Requirements of the Arab Pharmacovigilance Guidelines Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • On 1 July 2015, the Common Arab Guidelines on good vigilance practices became effective.
  • The Guidelines represented fundamental changes to pharmacovigilance practice and followed many aspects of the EU guidelines of June 2012.
  • This intensive two-day course will look at the various topics and their practical application from the perspective of compliance with the requirements of the Regulatory Authorities.

FSIS Highlights 2023 Accomplishments in Protecting Public Health and Strengthening the Food Supply Chain

Retrieved on: 
Wednesday, January 31, 2024

Washington, D.C., Jan. 31, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) today announced its key achievements in 2023 that protected public health through food safety and strengthened the food supply chain.

Key Points: 
  • Washington, D.C., Jan. 31, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) today announced its key achievements in 2023 that protected public health through food safety and strengthened the food supply chain.
  • The goal was to increase access to regulatory information and best practices to maintain and enhance food safety and strengthen the food supply chain.
  • In partnership with USDA’s Food and Nutrition Service, FSIS incorporated culturally appropriate food safety information in boxes delivered through the Food Distribution Program in Tribal communities.
  • FSIS protected public health by conducting ante-mortem and post-mortem inspection of 161 million head of livestock and 9.8 billion poultry carcasses.

Kindeva Drug Delivery Launches New Analytical Services Global Business Unit

Retrieved on: 
Wednesday, January 31, 2024

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.
  • For more than half a century, Kindeva has developed significant knowledge, experience, and expertise working on inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply.
  • Additionally, Kindeva has built deep expertise and capability in cGMP analytical services supporting its product development and supply partners.
  • In addition to increasing Kindeva’s global analytical footprint, Kindeva’s recently opened 32,000-square-foot state-of-the-art laboratories in Woodbury, Minnesota, will serve as the central hub for its expanded suite of stand-alone analytical services.

JEDEC Wide Bandgap Power Semiconductor Committee Publishes a Milestone Document for Reverse Bias Reliability Evaluation Procedures for Gallium Nitride Power Conversion Devices

Retrieved on: 
Tuesday, January 30, 2024

JEDEC Solid State Technology Association , the global leader in the development of standards for the microelectronics industry, today announced the publication of JEP198: Guideline for Reverse Bias Reliability Evaluation Procedures for Gallium Nitride Power Conversion Devices.

Key Points: 
  • JEDEC Solid State Technology Association , the global leader in the development of standards for the microelectronics industry, today announced the publication of JEP198: Guideline for Reverse Bias Reliability Evaluation Procedures for Gallium Nitride Power Conversion Devices.
  • JEP198 presents guidelines for evaluating the Time Dependent Breakdown (TDB) reliability of GaN power transistors.
  • It is applicable to planar enhancement-mode, depletion-mode, GaN integrated power solutions, and cascode GaN power transistors.
  • This publication covers suggested stress conditions and related test parameters for evaluating the TDB reliability of GaN power transistors using the off-state bias.